MedPath

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Phase 3
Completed
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Registration Number
NCT00347425
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
286
Inclusion Criteria
  • Males or females, 18-65 years, meeting DSM-IV TR diagnosis of Schizophrenia or Schizoaffective Disorder for whom a switch is indicated
Exclusion Criteria
  • Acutely psychotic or with a current Axis I primary psychiatric diagnosis other than schizophrenia or schizoaffective disorder based on DSM-IV TR criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AAripiprazole-
AOlanzapine-
ARisperidone-
AQuetiapine-
BAripiprazole-
BOlanzapine-
BRisperidone-
BZiprasidone-
AZiprasidone-
BQuetiapine-
Primary Outcome Measures
NameTimeMethod
Successful switch defined as those who complete the 4 weeks core study with no worsening of 2 successive post baseline assessments on the CGIS, exacerbation of EPS, or cardiovascular risk factors (body weight and fasting triglycerides) from baseline.4 weeks
Secondary Outcome Measures
NameTimeMethod
Adverse events26 weeks

Trial Locations

Locations (122)

Site 148

🇺🇸

Birmingham, Alabama, United States

Site 194

🇺🇸

Little Rock, Arkansas, United States

Site 178

🇺🇸

Anaheim, California, United States

Site 167

🇺🇸

Cerritos, California, United States

Site 189

🇺🇸

Cerritos, California, United States

Site 183

🇺🇸

Culver City, California, United States

Site 140

🇺🇸

Garden Grove, California, United States

Site 162

🇺🇸

La Palma, California, United States

Site 190

🇺🇸

Long Beach, California, United States

Site 173

🇺🇸

Oceanside, California, United States

Scroll for more (112 remaining)
Site 148
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.